International REgistry of COnservative or Radical Treatment of Localized Kidney Tumors
Recruiting now
Conditions studied: Kidney Cancer
In brief
Partial nephrectomy (PN) is the standard treatment for localized renal masses and should be preferred in clinical T1 (\<7 cm tumor diameter) renal tumors over radical nephrectomy (RN) whenever technically feasible. Nonetheless, indications, approaches, techniques for PN, and correct reporting of outcomes, are still a matter of great debate within the urology community. Concurrently, case-report series suggested that alternative strategies for the treatment of localized renal tumors (ablation techniques (AT), watchful waiting (WW), active surveillance (AS)) could be feasible with acceptable oncologic outcomes in particular settings of patients with localized renal tumors. In this complex clinical scenario, the role surgeon-related and environmental factors (such as surgical experience, hospital resources, countries' social background and performance of health system) are important to address the best personalized approach in patients with renal tumors. In the light of current evidence, many unsolved questions still remain and many unmet needs must be addressed. In particular, 1) the risk-benefit trade-offs between PN and RN for anatomically complex renal localized tumors; 2) the definition of evidence-based strategies to tailor the management strategy (AT vs WW vs AS vs surgery) in different subset of patients with particular clinical conditions (i.e. old, frail, comorbid patients); and 3) the definition of evidence-based recommendations to adapt surgical approach (open vs laparoscopic vs robotic) and resection techniques to different patient-, tumor-, and surgeon-specific characteristics. To meet the challenges, to overcome the limitations of current kidney cancer literature (such as the retrospective study design, potential risk of biases, and heterogeneous follow-up of most series), and to provide high-quality evidence for future development of effective clinical practice Guidelines, we designed the international REgistry of COnservative or Radical treatment of localized kiDney tumors (i-RECORD) Project. The expected impact of the i-RECORD project is to provide robust evidence on the leading clinical and environmental factors driving selection of the management strategy in patients with kidney cancer, and the differential impact of different management strategies (including AS, WW, AT, PN and RN) on functional, perioperative and oncological outcomes, as well as quality of life assessment, at a mid-long term follow-up (5-10 years).
Key facts
- Study ID
- NCT05363657
- Run by
- Azienda Ospedaliero-Universitaria Careggi
- People needed
- 10000
- Starts
- 2022-01-10
- Expected to finish
- 2028-12-31
- Last updated by the study team
- 2022-05-06
Who can join
Age: 18 and older. Sex: any. Healthy volunteers: not accepted.
You may qualify if…
- Radiological diagnosis of renal tumor susceptible to active treatment or AS/WW.
- Age ≥18 years
- Informed consent signed
You may not qualify if…
- Patient refuse to participate in clinical research.
- Urothelial renal carcinoma.
Where it is running
- Guy's Hospital — London, United Kingdom (enrolling)
- University of California San Diego, Moores Cancer Center — San Diego, California, United States (enrolling)
- N.N. Blokhin National Medical Research Center of Oncology — Moscow, Russia (enrolling)
- NG Teng Fong General Hospital — Singapore, Singapore (enrolling)
- Fundaciò Puigvert — Barcelona, Spain (enrolling)
- Hospital Universitario Ramón y Cajal, University of Alcalá — Madrid, Spain (enrolling)
- Bristol Urological Institute — Bristol, United Kingdom (enrolling)
- Institute of Urology, University of Southern California. — Los Angeles, California, United States (enrolling)
- VCU Health System — Richmond, Virginia, United States (enrolling)
- Medical University of Vienna, Vienna General Hospital — Vienna, Austria (enrolling)
- University of Bruxelles — Brussels, Belgium (enrolling)
- Onze Lieve Vrouw Hospital — Leuven, Belgium (enrolling)
- Santa Casa da Misericórdia de Fortaleza — Fortaleza, Brazil (enrolling)
- University of Patras — Pátrai, Greece (enrolling)
- Urology, Andrology & Kidney Transplantation Unit, University of Bari — Bari, Italy (enrolling)
- Policlinico S. Orsola Malpighi — Bologna, Italy (enrolling)
- Department of Urology, University of Florence, Unit of Oncologic Minimally-Invasive Urology and Andrology, Careggi Hospital — Florence, Italy (enrolling)
- Policlinico Riuniti, Università di Foggia. — Foggia, Italy (enrolling)
- Division of Urology, University of Genoa,Policlinico San Martino Hospital — Genova, Italy (enrolling)
- Azienda Ospedaliera Policlinico "G. Martino", Università di Messina. — Messina, Italy (enrolling)
- San Raffaele Scientific Institute, Milan, Italy; Division of Experimental Oncology/Unit of Urology, URI, IRCCS San Raffaele Hospital — Milan, Italy (enrolling)
- Policlinico Istituto Europeo di Oncologia (IEO) — Milan, Italy (enrolling)
- Istituto Nazionale dei Tumori Fondazione Senatore "G. Pascale" — Naples, Italy (enrolling)
- Institute Oncology Veneto (IOV) — Padova, Italy (enrolling)
- Humanitas Hospital — Rozzano, Italy (enrolling)
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.